Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients.
Montarolo F, Perga S, Martire S, Navone DN, Marchet A, Leotta D, Bertolotto A
This study measures NR4A gene levels in the blood of adults with Parkinson's or Alzheimer's disease and finds that these genes are generally lower in Parkinson's patients compared to healthy controls. It does not provide information on children, developmental outcomes, or treatments for NR4A2-related syndromes.
- NR4A1, NR4A2, and NR4A3 levels are reduced in the blood of Parkinson's patients.
- Only NR4A1 is reduced in Alzheimer's patients compared to healthy controls.
- The study focuses on adult neurodegenerative diseases, not pediatric developmental disorders.
- No clinical interventions or treatment outcomes for NR4A2 variants are reported.
Dopaminergic Neuronal Differentiation from the Forebrain-Derived Human Neural Stem Cells Induced in Cultures by Using a Combination of BMP-7 and Pramipexole with Growth Factors.
Yang H, Wang J, Wang F, Liu X, Chen H, Duan W, Qu T
This study shows that a specific chemical combination can successfully convert human fetal stem cells into dopamine-releasing neurons in a lab dish. The resulting neurons produce and release dopamine at levels higher than control groups, demonstrating the protocol's effectiveness for generating these specific cell types.
- The protocol uses BMP-7, pramipexole, and growth factors to drive stem cell differentiation.
- About 25% of cells become tyrosine hydroxylase-positive neurons within 24 hours.
- Generated neurons release significant amounts of dopamine under basal and stimulated conditions.
- This is a preclinical study using fetal human neural stem cells in culture.
Nurr1-Based Therapies for Parkinson's Disease.
Dong J, Li S, Mo JL, Cai HB, Le WD
This review summarizes preclinical evidence that activating the Nurr1 protein or using gene therapy can protect dopamine neurons and improve symptoms in animal models of Parkinson's disease. It highlights potential drug targets and pathways that may enhance these protective effects, but it does not report results from human clinical trials.
- Nurr1 is critical for developing and surviving midbrain dopamine neurons.
- Preclinical studies show Nurr1 activators protect neurons from injury.
- Gene therapy approaches show promise in animal models of Parkinson's disease.
- Several molecular pathways may enhance the effectiveness of Nurr1-based therapies.
- This is a review of laboratory research, not human clinical data.
Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.
Wang J, Bi W, Zhao W, Varghese M, Koch RJ, Walker RH, Chandraratna RA, Sanders ME, Janesick A, Blumberg B, Ward L, Ho L, Pasinetti GM
The drug IRX4204 activates the Nurr1 pathway and protects dopamine-producing neurons in rat models of Parkinson's disease. This preclinical study demonstrates that the compound crosses the blood-brain barrier and improves motor symptoms in animals, but it has not yet been tested in humans with NR4A2-related syndromes.
- IRX4204 activates Nurr1 signaling to support dopamine neuron survival in lab cultures.
- The drug crosses the blood-brain barrier and reaches effective concentrations in the brain.
- Treatment improves motor deficits in a rat model of Parkinson's disease.
- No human clinical trials or data for NR4A2-related conditions are reported.
Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.
Oh SM, Chang MY, Song JJ, Rhee YH, Joe EH, Lee HS, Yi SH, Lee SH
This study demonstrates that co-expressing Nurr1 and Foxa2 genes enhances the survival and function of dopaminergic neurons in animal models of Parkinson's disease. The findings suggest a potential gene-therapy strategy for restoring dopamine production, but the work remains preclinical and has not been tested in humans with NR4A2-related syndromes.
- Nurr1 and Foxa2 genes work together to support dopaminergic neuron survival in mice.
- The combined gene approach shows greater efficacy than using Nurr1 alone in animal models.
- This research focuses on Parkinson's disease mechanisms, not NR4A2 developmental disorders.
- No human clinical trials or patient data are included in this study.
Neuroprotective Transcription Factors in Animal Models of Parkinson Disease.
Blaudin de Thé FX, Rekaik H, Prochiantz A, Fuchs J, Joshi RL
This review identifies Nurr1 (NR4A2) and other transcription factors as critical regulators of midbrain dopamine neuron survival, suggesting that enhancing their protective signaling pathways could lead to new treatments for Parkinson's disease. It highlights that animal models lacking these genes replicate key features of the disease, providing a basis for testing neuroprotective strategies.
- Nurr1 regulates both development and adult survival of dopamine neurons in the brain.
- Mice missing Nurr1 show progressive loss of dopamine neurons similar to Parkinson's disease.
- Understanding these protective mechanisms helps identify potential new therapeutic targets.
- Protein transduction technology shows promise for delivering neuroprotective factors in animal models.
Role of Nurr1 in the Generation and Differentiation of Dopaminergic Neurons from Stem Cells.
Rodríguez-Traver E, Solís O, Díaz-Guerra E, Ortiz Ó, Vergaño-Vera E, Méndez-Gómez HR, García-Sanz P, Moratalla R, Vicario-Abejón C
This study demonstrates that introducing the Nurr1 gene into stem cells effectively generates dopaminergic neurons in a laboratory setting. These engineered neurons survive transplantation and restore motor function in mouse models of Parkinson's disease, particularly when combined with GDNF treatment.
- Nurr1 directs stem cells to become functional dopaminergic neurons in vitro.
- Transplanted Nurr1-generated neurons improve motor behavior in Parkinson's mice.
- GDNF treatment enhances the survival of these transplanted neurons.
- This approach offers a method for modeling neurodegeneration and testing therapies.
Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons.
Jiang H, Xu Z, Zhong P, Ren Y, Liang G, Schilling HA, Hu Z, Zhang Y, Wang X, Chen S, Yan Z, Feng J
Suppressing the p53 protein and arresting cell division significantly improves the efficiency of converting human skin cells into dopamine-producing neurons using Nurr1 and other factors. This method generates functional midbrain dopaminergic neurons that could serve as patient-specific models for Parkinson's disease research.
- Nurr1 is one of four factors used to reprogram human fibroblasts into dopaminergic neurons.
- Inhibiting p53 and inducing G1 cell cycle arrest markedly increases conversion efficiency.
- The process relies on the enzyme Tet1 for successful epigenetic reprogramming.
- Resulting neurons express midbrain markers and exhibit active dopamine transmission.
- This technique aims to create patient-specific cells for Parkinson's disease therapy research.
Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells.
Oliveira LM, Falomir-Lockhart LJ, Botelho MG, Lin KH, Wales P, Koch JC, Gerhardt E, Taschenberger H, Outeiro TF, Lingor P, Schüle B, Arndt-Jovin DJ, Jovin TM
Excess alpha-synuclein in Parkinson's patient stem cells impairs the development of dopamine neurons and reduces the expression of NURR1, a protein also affected by NR4A2 mutations. This study demonstrates that high levels of alpha-synuclein disrupt neuronal maturation pathways relevant to dopaminergic function.
- SNCA triplication increases alpha-synuclein, impairing dopamine neuron differentiation in patient stem cells.
- NURR1 mRNA levels decrease significantly when alpha-synuclein is overexpressed.
- Patient cells show reduced neurite outgrowth and lower neuronal activity compared to controls.
- The study uses human-derived induced pluripotent stem cells, not animal models.
A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro.
Hammond SL, Safe S, Tjalkens RB
The compound C-DIM12 activates the NR4A2 protein and increases the expression of dopamine-related genes in cultured neurons. It also protects these cells from chemical damage in laboratory experiments.
- C-DIM12 activates NR4A2 to boost dopamine gene expression in neurons.
- The compound protects dopaminergic neurons from toxin-induced damage in vitro.
- This is a preclinical study using cell lines, not human patients.
- No clinical data or human trials are reported.
Dopamine Agonists Exert Nurr1-inducing Effect in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
Zhang LM, Sun CC, Mo MS, Cen L, Wei L, Luo FF, Li Y, Li GF, Zhang SY, Yi L, Huang W, Liu ZL, Le WD, Xu PY
Dopamine agonist medications increase Nurr1 (NR4A2) gene expression in the blood cells of Parkinson's patients. This effect occurs both in living patients taking these drugs and in laboratory cultures treated with pramipexole. The findings suggest that dopamine agonists may protect brain neurons by boosting NR4A2 levels.
- Dopamine agonists significantly raise Nurr1 mRNA levels in patient blood cells.
- L-dopa treatment also increases Nurr1 expression compared to untreated patients.
- Pramipexole rapidly boosts Nurr1 levels in cultured blood cells within hours.
- Increased Nurr1 may explain how dopamine drugs protect dopaminergic neurons.
The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells.
Hou Y, Li W, Sheng Y, Li L, Huang Y, Zhang Z, Zhu T, Peace D, Quigley JG, Wu W, Zhao YY, Qian Z
The transcription factor Foxm1 maintains blood stem cell stability by directly activating the NR4A2 gene, and reducing Foxm1 levels disrupts this balance. This study identifies a direct molecular link between Foxm1 and NR4A2 in human cells, confirming that NR4A2 expression is regulated upstream by Foxm1.
- Foxm1 directly binds to the NR4A2 gene promoter to drive its transcription.
- Reducing Foxm1 decreases NR4A2 levels and disrupts blood stem cell stability in human cells.
- Restoring NR4A2 expression reverses the defects caused by low Foxm1 levels.
- Low Foxm1 correlates with myelodysplastic syndrome, a blood disorder.
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.
Kim CH, Han BS, Moon J, Kim DJ, Shin J, Rajan S, Nguyen QT, Sohn M, Kim WG, Han M, Jeong I, Kim KS, Lee EH, Tu Y, Naffin-Olivos JL, Park CH, Ringe D, Yoon HS, Petsko GA, Kim KS
Two existing antimalarial drugs, amodiaquine and chloroquine, activate the Nurr1 protein to protect dopamine neurons and reduce inflammation in rats with Parkinson's disease. These treatments improve movement behaviors in the animal model without causing dyskinesia-like side effects.
- Amodiaquine and chloroquine directly bind to and activate the Nurr1 receptor.
- Activation boosts dopamine neuron gene expression and reduces neuroinflammation.
- Treatments improve motor deficits in a rat model of Parkinson's disease.
- No dyskinesia-like side effects are observed in the treated animals.
Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.
Oh SM, Chang MY, Song JJ, Rhee YH, Joe EH, Lee HS, Yi SH, Lee SH
Delivering Nurr1 and Foxa2 genes via virus in mice protects dopamine neurons and improves movement for at least one year. This preclinical study shows that these two factors work together to shield brain cells from damage.
- Nurr1 and Foxa2 protect dopamine neurons from toxicity when expressed together.
- Gene therapy using viruses delivered these factors to mouse brains effectively.
- Motor behaviors improved significantly in the Parkinson's disease mouse model.
- Protection lasted for at least one year in the treated animals.
Vitamin C facilitates dopamine neuron differentiation in fetal midbrain through TET1- and JMJD3-dependent epigenetic control manner.
He XB, Kim M, Kim SY, Yi SH, Rhee YH, Kim T, Lee EH, Park CH, Dixit S, Harrison FE, Lee SH
Vitamin C promotes the development of dopamine neurons in fetal brain tissue by triggering specific epigenetic changes that activate genes controlled by Nurr1. This process relies on the enzymes TET1 and JMJD3 to modify DNA and histones, making these genes more accessible for expression.
- Vitamin C boosts dopamine neuron differentiation in embryonic midbrain stem cells.
- The effect depends on epigenetic modifications by TET1 and JMJD3 enzymes.
- Nurr1 activity increases as gene promoters become more accessible via these changes.
- Mice lacking the Vitamin C transporter show reduced dopamine neuron formation.
- This mechanism links cellular metabolism directly to neural development pathways.
A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).
Smith GA, Rocha EM, Rooney T, Barneoud P, McLean JR, Beagan J, Osborn T, Coimbra M, Luo Y, Hallett PJ, Isacson O
A drug that activates the Nurr1 protein protects dopamine-producing neurons and reduces brain inflammation in rats with a Parkinson's disease model. This preclinical study demonstrates that boosting Nurr1 activity can prevent nerve cell loss and calm immune cells in the brain.
- The Nurr1 agonist SA00025 entered the rat brain and activated dopamine-related genes.
- Treatment partially protected dopamine neurons from damage caused by inflammation and toxins.
- The drug reduced markers of microglial and astrocyte activation in the brain.
- This is a preclinical animal study, not a human clinical trial.
Direct conversion of human fibroblasts into dopaminergic neural progenitor-like cells using TAT-mediated protein transduction of recombinant factors.
Mirakhori F, Zeynali B, Rassouli H, Salekdeh GH, Baharvand H
Researchers successfully converted human skin cells into dopaminergic neural progenitor-like cells using protein transduction and small molecules. This method generates cells that express key midbrain markers, including NURR1, offering a potential source for cell replacement therapies in neurodegenerative diseases.
- Human fibroblasts convert directly into dopaminergic progenitor-like cells using SOX2 and LMX1a proteins.
- Generated cells express midbrain markers like NURR1, PITX3, and TH after differentiation.
- The technique uses TAT-mediated protein transduction combined with small molecules in 3D culture.
- This approach offers a potential alternative strategy for cell therapy in neurodegenerative disorders.
Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease.
De Miranda BR, Popichak KA, Hammond SL, Miller JA, Safe S, Tjalkens RB
A specific chemical compound (C-DIM12) protects dopamine-producing neurons and reduces brain inflammation in a mouse model of Parkinson's disease. The drug works by activating the NR4A2 protein to stop glial cell activation and support neuron health, even when treatment starts after damage has begun.
- C-DIM12 prevents loss of dopamine neurons in mice exposed to neurotoxins.
- The compound suppresses inflammatory glial cells that typically damage neurons.
- Treatment remains effective even when started after initial toxin exposure.
- The drug activates NR4A2 to maintain dopamine neuron function and identity.
Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease.
Glaab E, Schneider R
This study identifies NR4A2 as the most significantly under-expressed gene in Parkinson's disease brain tissue, suggesting that age-related declines in this factor may increase disease risk through mechanisms similar to genetic mutations. The research highlights shared molecular pathways between normal aging and Parkinson's disease, pointing to potential biomarkers for early detection.
- NR4A2 is the most significantly under-expressed gene in Parkinson's disease brain tissue.
- Age-related NR4A2 decline may increase Parkinson's risk via mechanisms similar to genetic mutations.
- The study finds shared pathway alterations between normal aging and Parkinson's disease.
- Researchers identify potential biomarkers for oxidative stress linked to aging and Parkinson's.
A high-efficiency induction of dopaminergic cells from human umbilical mesenchymal stem cells for the treatment of hemiparkinsonian rats.
Ko TL, Fu YY, Shih YH, Lin YH, Ko MH, Fu TW, Lin TY, Hsiao HS, Chu PM, Fu YS
Overexpressing Nurr1 in human umbilical stem cells significantly increases their conversion into dopamine-producing neurons and improves motor symptoms in rats with Parkinson's-like damage. This approach demonstrates that enhancing Nurr1 levels can boost the yield of therapeutic dopaminergic cells for potential transplantation.
- Nurr1 overexpression raises dopaminergic cell conversion rates from 12% to 71%.
- Transplanted cells survive for at least three months in rat brains.
- Treated rats show improved motor behavior compared to untreated controls.
- The study uses human umbilical stem cells, not patient-derived cells.
Midbrain cues dictate differentiation of human dental pulp stem cells towards functional dopaminergic neurons.
Kanafi M, Majumdar D, Bhonde R, Gupta P, Datta I
Human dental pulp stem cells differentiate into functional dopaminergic neurons when exposed to specific midbrain signaling cues. These induced cells express key dopaminergic markers, secrete dopamine in response to stimulation, and exhibit calcium influx consistent with neuronal activity.
- Dental pulp stem cells convert to dopaminergic neurons using midbrain growth factors.
- Induced cells express Nurr1, Pitx3, En1, and tyrosine hydroxylase markers.
- Approximately 77% of treated cells become tyrosine hydroxylase-positive.
- Cells secrete dopamine upon stimulation with potassium chloride or ATP.
- This demonstrates a potential source for cell-based therapies in neurodegeneration.
The Shh coreceptor Cdo is required for differentiation of midbrain dopaminergic neurons.
Kwon YR, Jeong MH, Leem YE, Lee SJ, Kim HJ, Bae GU, Kang JS
The protein Cdo is essential for the development of midbrain dopamine neurons by enabling Sonic hedgehog signaling. Without Cdo, stem cells produce fewer dopamine neurons and show reduced expression of key regulators including Nurr1 (NR4A2). Boosting this signaling pathway can restore dopamine neuron production in cells lacking Cdo.
- Cdo is required for proper differentiation of midbrain dopaminergic neurons.
- Lack of Cdo reduces expression of NR4A2 and other dopamine regulators.
- Activating the Shh pathway restores dopamine neuron development in deficient cells.
Impact of circadian nuclear receptor REV-ERBα on midbrain dopamine production and mood regulation.
Chung S, Lee EJ, Yun S, Choe HK, Park SB, Son HJ, Kim KS, Dluzen DE, Lee I, Hwang O, Son GH, Kim K
This study identifies a molecular mechanism where the circadian protein REV-ERBα competes with NURR1 (NR4A2) to regulate dopamine production in mice. Inhibition of this interaction leads to increased dopamine and mania-like behaviors, highlighting a potential pathway for mood regulation.
- REV-ERBα competes with NURR1 to repress dopamine-producing enzyme transcription.
- Blocking REV-ERBα increases dopamine levels and causes mania-like behavior in mice.
- The findings link circadian rhythms to mood disorders via dopaminergic pathways.
- This is preclinical research using mouse models, not human clinical data.
Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease.
Schlaudraff F, Gründemann J, Fauler M, Dragicevic E, Hardy J, Liss B
This study analyzes gene expression in dopamine neurons from human Parkinson's disease brains, finding that elevated alpha-synuclein correlates with increased activity in cellular cleanup pathways. It confirms that miR-133b levels remain unchanged in these specific neurons during the disease process.
- Researchers analyzed mRNA and microRNA levels in single dopamine neurons from human Parkinson's patients.
- Elevated alpha-synuclein correlates with increased proteasomal and lysosomal function mRNAs.
- These changes may help counteract toxicity from accumulated alpha-synuclein proteins.
- miR-133b levels do not change in dopamine neurons of Parkinson's patients.
- The study uses a statistical model to account for age and RNA quality differences.
Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation.
Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y, Sekiguchi K, Nakagawa M, Parmar M, Takahashi J
Researchers isolate midbrain dopaminergic progenitor cells from human stem cells using the CORIN marker to ensure safety and efficacy for transplantation. Transplanted sorted cells survive, differentiate into dopamine neurons, and improve motor behavior in rat models without forming tumors. This approach offers a scalable and safe method for generating donor cells for potential cell replacement therapies.
- Human stem cells yield dopaminergic progenitors when sorted by the CORIN marker.
- Sorted cells express key midbrain markers FOXA2 and LMX1A in culture.
- Transplanted cells survive and function as dopamine neurons in rat models.
- Treatment improves motor behavior without causing tumor formation in animals.
- NURR1-positive progenitors show the best survival and functional outcomes.
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.
Decressac M, Volakakis N, Björklund A, Perlmann T
This review explains how the NR4A2 protein helps maintain dopamine neuron health and suggests that its dysfunction contributes to Parkinson's disease progression. It highlights NR4A2 as a potential therapeutic target for restoring dopaminergic function in neurodegenerative conditions.
- NR4A2 maintains identity and function of midbrain dopamine neurons.
- Impaired NR4A2 function links to early Parkinson's disease pathology.
- NR4A2 downregulation occurs alongside alpha-synuclein accumulation.
- The protein is a potential target for future therapeutic interventions.
Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.
McFarland K, Spalding TA, Hubbard D, Ma JN, Olsson R, Burstein ES
Low doses of the cancer drug bexarotene rescue dopamine neurons and reverse behavioral deficits in rat models of Parkinson's disease. The study suggests that these low doses have milder side effects than those used in cancer therapy, potentially making them a viable treatment option for Parkinson's.
- Bexarotene rescues dopamine neurons and improves behavior in Parkinson's rats at low doses.
- Low doses cause significantly fewer side effects than high cancer-treatment doses.
- The drug works by interacting with Nurr1-RXR heterodimers rather than binding Nurr1 directly.
Constraining the Pluripotent Fate of Human Embryonic Stem Cells for Tissue Engineering and Cell Therapy - The Turning Point of Cell-Based Regenerative Medicine.
Parsons XH
This study demonstrates a method to efficiently convert human embryonic stem cells into pure populations of neurons or heart muscle cells using specific small molecules. It identifies that retinoic acid drives neuronal development by promoting the nuclear entry of Nurr1 (NR4A2), suggesting a mechanism for generating transplantable neural tissue.
- Retinoic acid induces human embryonic stem cells to become neurons efficiently.
- This process relies on Nurr1 (NR4A2) moving into the cell nucleus.
- Nicotinamide similarly directs stem cells to become beating heart muscle cells.
- The method produces high-purity, clinically relevant cell populations for therapy.
Engraftment of mouse embryonic stem cells differentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats.
Tripathy D, Haobam R, Nair R, Mohanakumar KP
Transplanting dopamine-producing neurons derived from mouse embryonic stem cells into rats with Parkinson-like symptoms improves motor behavior and protects surviving brain cells. The study demonstrates that these grafted cells express key dopaminergic markers, including NURR1, and contribute to functional recovery in the animal model.
- Differentiated mouse stem cells survive and function as dopamine neurons in parkinsonian rats.
- Transplants reduce abnormal movements and protect against dopamine loss in the brain.
- NURR1 expression confirms the dopaminergic identity of the grafted cells.
- Astrocytosis and microglial activity likely support graft survival and recovery.
α7 nicotinic receptor agonist reactivates neurogenesis in adult brain.
Narla S, Klejbor I, Birkaya B, Lee YW, Morys J, Stachowiak EK, Terranova C, Bencherif M, Stachowiak MK
An experimental drug targeting alpha-7 nicotinic receptors stimulates the production of new neurons in adult mouse brains, including those resembling the dopaminergic cells affected in NR4A2-related syndromes. This preclinical study demonstrates that activating these receptors can reactivate developmental signaling pathways to promote neuronal differentiation.
- The drug TC-7020 activates alpha-7 nicotinic receptors in adult mouse brains.
- Treatment increases the generation of new neurons in multiple brain regions.
- New neurons include those with dopaminergic characteristics similar to Nurr1+ cells.
- The mechanism involves reactivating developmental FGFR1 signaling pathways.
- This is a preclinical study using mice, not humans.
Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.
Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, Moore M, Osborn T, Cooper O, Spealman R, Hallett P, Isacson O
Researchers improve the safety and efficiency of creating dopaminergic neurons from stem cells by using specific surface markers to sort the desired cells. This sorting method enriches for midbrain dopamine neurons that successfully restore motor function in animal models without forming tumors.
- Sorting stem-cell-derived neurons with NCAM and CD29 markers increases purity of target dopamine cells.
- Sorted cells show higher expression of key developmental genes like NURR1, FOXA2, and PITX3.
- Transplanted sorted neurons restore motor function in rat models of Parkinson's disease.
- Primate-derived cells survive long-term in host brains without immunosuppression or tumor formation.
Rapid generation of functional dopaminergic neurons from human induced pluripotent stem cells through a single-step procedure using cell lineage transcription factors.
Theka I, Caiazzo M, Dvoretskova E, Leo D, Ungaro F, Curreli S, Managò F, Dell'Anno MT, Pezzoli G, Gainetdinov RR, Dityatev A, Broccoli V
Researchers developed a rapid, single-step method to convert human stem cells into functional dopaminergic neurons using transcription factors including NURR1. This approach generates mature dopamine-releasing neurons in just 21 days with over 93% efficiency, bypassing traditional complex differentiation stages. The technique provides a streamlined platform for disease modeling and high-throughput drug screening.
- NURR1 is one of three transcription factors used to create dopaminergic neurons from stem cells.
- The new protocol produces functional neurons in 21 days, significantly faster than existing methods.
- Over 93% of treated cells successfully convert into mature, dopamine-releasing neurons.
- This method enables efficient disease modeling and high-throughput drug screening for neurological conditions.
Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages.
Stott SR, Metzakopian E, Lin W, Kaestner KH, Hen R, Ang SL
Removing Foxa1 and Foxa2 in mouse midbrain neurons causes them to lose their ability to produce dopamine without dying. This loss of function occurs because these genes are required for Nurr1 (NR4A2) to bind to the DNA and activate dopamine-related genes. The study confirms a direct molecular link between Foxa factors and NR4A2 activity in maintaining dopaminergic identity.
- Foxa1 and Foxa2 deletion reduces dopamine-producing neurons in mouse substantia nigra.
- Neurons survive but lose their dopaminergic phenotype, not due to cell death.
- Loss of Foxa genes prevents Nurr1 from binding to the TH gene promoter.
- This mechanism explains how NR4A2 activity is maintained in mature midbrain neurons.
Conditioned medium from human amniotic epithelial cells may induce the differentiation of human umbilical cord blood mesenchymal stem cells into dopaminergic neuron-like cells.
Yang S, Sun HM, Yan JH, Xue H, Wu B, Dong F, Li WS, Ji FQ, Zhou DS
Conditioned medium from human amniotic cells directs umbilical cord stem cells to become dopamine-producing neurons in a dish, and these modified cells improve movement symptoms in rats with Parkinson's disease. This preclinical study identifies specific growth factors (NGF and BDNF) that drive this cellular transformation.
- Amniotic cell medium converts umbilical cord stem cells into dopamine neuron-like cells.
- The process relies on NGF and BDNF growth factors found in the amniotic medium.
- Transplanted modified cells reduce behavioral deficits in Parkinson's disease rats.
- This is a preclinical animal study, not human clinical evidence.
Intellectual disability and hemizygous GPD2 mutation.
Barge-Schaapveld DQ, Ofman R, Knegt AC, Alders M, Höhne W, Kemp S, Hennekam RC
This case report identifies a deletion on chromosome 2q that includes the NR4A2 gene alongside GPD2 in a patient with intellectual disability and developmental disorders. The study highlights the diagnostic challenge of distinguishing which gene variant causes the symptoms when multiple genetic changes are present.
- The patient has a de novo deletion containing both NR4A2 and GPD2 genes.
- A separate GPD2 mutation was found but also present in healthy family members.
- Functional tests showed absent GPD2 activity in the patient only.
- The study concludes evidence for GPD2 causality is circumstantial, not definitive.
- High diagnostic costs underscore the need for better genotype-phenotype databases.
The N-terminal region of Nurr1 (a.a 1-31) is essential for its efficient degradation by the ubiquitin proteasome pathway.
Alvarez-Castelao B, Losada F, Ahicart P, Castaño JG
The study identifies a specific region at the start of the NR4A2 protein that signals for its destruction within cells. Removing this region stabilizes the protein, allowing it to persist longer and maintain its normal function in laboratory models.
- An N-terminal segment (amino acids 1-31) targets NR4A2 for rapid degradation by cellular machinery.
- Deleting this segment significantly extends the protein's lifespan and increases its steady-state levels.
- The stabilized mutant retains full transcriptional activity compared to the normal protein.
- Researchers propose this stable variant as a potential candidate for gene therapy in Parkinson's disease.
Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model.
Shetty P, Thakur AM, Viswanathan C
Differentiated umbilical cord stem cells that produce dopamine improve symptoms in rats with Parkinson's disease. This preclinical study suggests these specific cell types may be a viable future therapy for neurodegenerative conditions involving dopamine loss.
- Umbilical cord stem cells differentiate into dopamine-producing cells more effectively than bone marrow cells.
- Treated rats showed improved Parkinsonian symptoms over a one-year period.
- The study uses an animal model, not human patients or NR4A2 genetics.
- Results indicate potential for cell therapy but require clinical validation.
Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons.
Kadkhodaei B, Alvarsson A, Schintu N, Ramsköld D, Volakakis N, Joodmardi E, Yoshitake T, Kehr J, Decressac M, Björklund A, Sandberg R, Svenningsson P, Perlmann T
Removing the Nurr1 protein in adult dopamine neurons causes progressive damage to nerve fibers and reduces dopamine levels, leading to motor deficits. This process occurs because Nurr1 is required to maintain mitochondrial function within these cells.
- Nurr1 ablation in mature dopamine neurons causes progressive axon and dendrite damage.
- Loss of Nurr1 leads to reduced dopamine levels and impaired motor behavior in mice.
- Nurr1 primarily regulates nuclear-encoded mitochondrial genes to sustain cellular energy production.
- This study uses a mouse model, not human clinical data.
Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells.
Andersson ER, Saltó C, Villaescusa JC, Cajanek L, Yang S, Bryjova L, Nagy II, Vainio SJ, Ramirez C, Bryja V, Arenas E
Wnt1 and Wnt5a signaling pathways cooperate to drive the development of midbrain dopaminergic neurons in mice. This interaction enhances the generation of these specific neurons from stem cells, suggesting a potential strategy for improving stem cell-based therapies for Parkinson's disease.
- Wnt1 and Wnt5a work together to promote midbrain dopaminergic neuron development in vivo.
- Loss of both genes causes greater neuron loss than loss of either gene alone.
- Coordinated Wnt signaling improves the generation of dopaminergic neurons from stem cells.
- Findings suggest potential applications for stem cell therapies targeting Parkinson's disease.
α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.
Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A
This study shows that Nurr1 is essential for dopamine neurons to respond to GDNF, a growth factor currently in clinical trials for Parkinson's disease. When Nurr1 levels drop, the cells lose their ability to receive protective signals from GDNF, making them vulnerable to damage.
- Nurr1 regulates the expression of Ret, the receptor required for GDNF signaling.
- Reduced Nurr1 blocks dopamine neurons' response to GDNF protection.
- Restoring Nurr1 levels rescues GDNF signaling and protects neurons from toxicity.
- Ret expression is also reduced in the brains of Parkinson's patients.